USAQ 最新10-Q变化
将 USAQ 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-05-14 与上一份 10-Q · 2025-11-13
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +16 | −27 | ~8 | 5 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 1 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)、法律诉讼、风险因素、其他信息
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-05-14
During the fourth quarter of 2020 we began to sell the AllergiEnd® Products, consisting of AllergiEnd® Allergy Diagnostics and Allergen Immunotherapy treatments, to physicians. During the second quarter of 2022, we began to enter into SaaS subscription agreements to provide physicians with access to…
Results of Operations during the three months ended March 31, 2026 as compared to the three months ended March 31, 2025.
For the period ended March 31, 2026, we generated revenues of $728,685 compared to $645,419 of revenues for the period ended March 31, 2025. The increase in revenues for the period ended March 31, 2026, is attributed to the growth of the revenue associated with ISP services which more than made up f…
Cost of revenues consists of the cost of the AllergiEnd® test kits and allergen immunotherapy pharmacy prepared treatment sets, shipping costs to our customers as well as administrative services and labor expenses directly related to ISP sales and the amortization of our capitalized software.
The Company generated gross profit of $470,803 for the three months ended March 31, 2026, compared to $429,944 for the three months ended March 31, 2025, an increase of $40,859, or 9.5%. Gross margin decreased from 66.6% for the three months ended March 31, 2025 to 64.6% for the three months ended M…
相对上期删除的文字 · 来源:10-Q · 2025-11-13
Results of Operations during the three and nine months ended September 30, 2025 as compared to the three and nine months ended September 30, 2024
During the fourth quarter of 2020 we began to sell the AllergiEnd® Products, consisting of AllergiEnd® Allergy Diagnostics and Allergen Immunotherapy treatments, to physicians. During the second quarter of 2022, we began to enter into SaaS subscription agreements to provide physicians with access to…
For the three months ended September 30, 2025, we generated revenues of $737,066 compared to $544,285 of revenues for the three months ended September 30, 2024 which was driven by a 122% increase in our ISP revenues during the period.
For the nine months ended September 30, 2025, we generated revenues of $1,987,931 compared to $1,505,945 of revenues for the nine months ended September 30, 2024. The increase in revenues in the first nine months of 2025 were attributed to a 74.9% increase in revenues generated from ISP services to …
Cost of revenues consists of the cost of AllergiEnd® test kits and allergen immunotherapy pharmacy prepared treatment sets, shipping costs to our customers as well as administrative services and labor expenses directly related to ISP sales and the amortization of our capitalized software.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议